• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞色素 P450 与阿片类药物相互作用的临床意义及疼痛管理策略。

The clinical implications of cytochrome p450 interactions with opioids and strategies for pain management.

机构信息

The Pain Center of Fairfield, Fairfield, Connecticut 06824, USA.

出版信息

J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S15-22. doi: 10.1016/j.jpainsymman.2012.08.012.

DOI:10.1016/j.jpainsymman.2012.08.012
PMID:23218232
Abstract

Pharmacokinetic differences among opioids influence a patient's response to opioid treatment. An important element affecting a drug's pharmacokinetics, its metabolism, may be altered under various circumstances, thereby enhancing or mitigating a patient's response to opioids. The genetic background of the metabolic enzymes involved in opioid metabolism, comorbid medical conditions, older age, and the presence of other drugs that influence metabolism are such factors that can cause the response to opioid therapy to vary greatly from the expected response to a standard dose. As a result of the variability in individual responses to opioids, clinical management of pain with opioids must be empirical.

摘要

阿片类药物之间的药代动力学差异会影响患者对阿片类药物治疗的反应。影响药物药代动力学的一个重要因素是其代谢,在不同情况下可能会发生改变,从而增强或减轻患者对阿片类药物的反应。参与阿片类药物代谢的代谢酶的遗传背景、合并的医疗状况、年龄较大以及存在影响代谢的其他药物等因素,可能导致阿片类药物治疗的反应与标准剂量的预期反应有很大差异。由于个体对阿片类药物的反应存在差异,因此必须根据经验来进行阿片类药物治疗疼痛的临床管理。

相似文献

1
The clinical implications of cytochrome p450 interactions with opioids and strategies for pain management.细胞色素 P450 与阿片类药物相互作用的临床意义及疼痛管理策略。
J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S15-22. doi: 10.1016/j.jpainsymman.2012.08.012.
2
Opioid therapies and cytochrome p450 interactions.阿片类药物治疗与细胞色素 p450 相互作用。
J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14. doi: 10.1016/j.jpainsymman.2012.08.013.
3
The metabolism of opioid agents and the clinical impact of their active metabolites.阿片类药物的代谢及其活性代谢物的临床影响。
Clin J Pain. 2011 Nov-Dec;27(9):824-38. doi: 10.1097/AJP.0b013e31821d8ac1.
4
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).阿片类药物与老年人慢性重度疼痛的管理:一个国际专家小组的共识声明,重点关注世界卫生组织第三阶梯临床最常用的六种阿片类药物(丁丙诺啡、芬太尼、氢吗啡酮、美沙酮、吗啡、羟考酮)。
Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.
5
Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.阿片类镇痛药临床疗效和耐受性的个体差异——药物相互作用和药物遗传学的重要性。
Scand J Pain. 2017 Oct;17:193-200. doi: 10.1016/j.sjpain.2017.09.009. Epub 2017 Oct 17.
6
Quantifying the impact of drug-drug interactions associated with opioids.量化与阿片类药物相关的药物相互作用的影响。
Am J Manag Care. 2011 Sep;17 Suppl 11:S288-92.
7
CYP2D6 in the metabolism of opioids for mild to moderate pain.CYP2D6 在治疗轻中度疼痛的阿片类药物代谢中的作用。
Pharmacology. 2011;87(5-6):274-85. doi: 10.1159/000326085. Epub 2011 Apr 15.
8
Opioid pharmacokinetic drug-drug interactions.阿片类药物药代动力学的药物相互作用。
Am J Manag Care. 2011 Sep;17 Suppl 11:S276-87.
9
Opioid switching and rotation in primary care: implementation and clinical utility.基层医疗中的阿片类药物转换与轮换:实施与临床应用
Curr Med Res Opin. 2009 Sep;25(9):2133-50. doi: 10.1185/03007990903120158.
10
The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.CYP2D6和OPRM1基因检测在阿片类药物治疗中的价值。
Clin Lab Med. 2008 Dec;28(4):581-98. doi: 10.1016/j.cll.2008.10.003.

引用本文的文献

1
Brain Cytochrome P450: Navigating Neurological Health and Metabolic Regulation.脑细胞色素P450:探索神经健康与代谢调节
J Xenobiot. 2025 Mar 14;15(2):44. doi: 10.3390/jox15020044.
2
Assessment of the drug-drug interaction potential for therapeutic proteins with pro-inflammatory activities.评估具有促炎活性的治疗性蛋白的药物-药物相互作用潜力。
Clin Transl Sci. 2023 Jun;16(6):922-936. doi: 10.1111/cts.13507. Epub 2023 Apr 23.
3
Acute Pain Management Pearls: A Focused Review for the Hospital Clinician.急性疼痛管理要点:针对医院临床医生的重点综述
Healthcare (Basel). 2022 Dec 22;11(1):34. doi: 10.3390/healthcare11010034.
4
Pharmacogenomics of Cancer Pain Treatment Outcomes in Asian Populations: A Review.亚洲人群癌症疼痛治疗结果的药物基因组学:综述
J Pers Med. 2022 Nov 18;12(11):1927. doi: 10.3390/jpm12111927.
5
Perioperative Pain Management and Opioid Stewardship: A Practical Guide.围手术期疼痛管理与阿片类药物管理:实用指南。
Healthcare (Basel). 2021 Mar 16;9(3):333. doi: 10.3390/healthcare9030333.
6
Characterization of structurally novel G protein biased CB agonists: Implications for drug development.结构新颖的 G 蛋白偏向 CB 激动剂的表征:对药物开发的影响。
Pharmacol Res. 2017 Nov;125(Pt B):161-177. doi: 10.1016/j.phrs.2017.08.008. Epub 2017 Aug 23.
7
A precision medicine approach to a patient with unresolved pain following orthopedic surgery: a case report.一种针对骨科手术后疼痛未缓解患者的精准医疗方法:病例报告
J Med Case Rep. 2017 Feb 24;11(1):50. doi: 10.1186/s13256-017-1207-5.
8
Guidelines for prescribing opioids for chronic non-cancer pain in Korea.韩国慢性非癌性疼痛阿片类药物处方指南。
Korean J Pain. 2017 Jan;30(1):18-33. doi: 10.3344/kjp.2017.30.1.18. Epub 2016 Dec 30.
9
A service improvement project to review prescribing information provided by general practitioners for new referrals to a UK National Health Service hospital pain clinic: potential implications of CYP2D6 enzyme inhibition.一项服务改进项目,旨在审查英国国家医疗服务体系医院疼痛诊所新转诊患者的全科医生提供的处方信息:CYP2D6酶抑制的潜在影响。
Br J Pain. 2016 Nov;10(4):222-231. doi: 10.1177/2049463716657364. Epub 2016 Jul 5.
10
The 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its Use.5%利多卡因贴剂:被纳入治疗局部神经性疼痛的国际治疗指南及其使用的临床证据
Pain Ther. 2016 Dec;5(2):149-169. doi: 10.1007/s40122-016-0060-3. Epub 2016 Nov 7.